Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the imaging calibration factor for quantitative SPECT/CT of actinium-225.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Angewandte Chemie (International ed. in English)·2026
Same author

Generic neural network model for estimating exposure levels in industrial environments.

Journal of radiological protection : official journal of the Society for Radiological Protection·2026
Same author

Phase 1 Dose-Escalation Study of [<sup>225</sup>Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

Molecular therapy. Oncology·2026
Same author

Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.

Frontiers in oncology·2026
Same journal

[<sup>68</sup>Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [<sup>68</sup>Ga]GaCl<sub>3</sub> from Cyclotron using Liquid Target: An Italian Experience.

Current radiopharmaceuticals·2025
Same journal

Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data.

Current radiopharmaceuticals·2025
Same journal

Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).

Current radiopharmaceuticals·2025
Same journal

Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [<sup>131</sup>I]Sodium Iodide.

Current radiopharmaceuticals·2025
Same journal

RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence.

Current radiopharmaceuticals·2025
Same journal

Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.

Current radiopharmaceuticals·2025
See all related articles

Related Experiment Video

Updated: May 26, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted alpha therapy with 213Bi.

Alfred Morgenstern1, Frank Bruchertseifer, Christos Apostolidis

  • 1European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany. alfred.morgenstern@ec.europa.eu

Current Radiopharmaceuticals
|December 29, 2011
PubMed
Summary
This summary is machine-generated.

Targeted alpha therapy using Bismuth-213 (213Bi) shows promise in preclinical and clinical studies. This review covers 213Bi production, generator systems, and clinical outcomes, highlighting its therapeutic potential.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: May 26, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical therapy
  • Oncology

Background:

  • Targeted alpha therapy (TAT) utilizes alpha-emitting radionuclides for cancer treatment.
  • Bismuth-213 (213Bi) is a promising alpha emitter with a short half-life suitable for targeted delivery.
  • Preclinical and clinical evidence supports the feasibility and efficacy of 213Bi-based therapies.

Purpose of the Study:

  • To review the production methods for Actinium-225 (225Ac) and 225Ac/213Bi radionuclide generators.
  • To provide an overview of preclinical studies investigating 213Bi targeted therapy.
  • To summarize current clinical experience and therapeutic outcomes with 213Bi.

Main Methods:

  • Review of literature on 225Ac and 225Ac/213Bi generator production.
  • Selection and summary of key preclinical studies on 213Bi targeted therapy.
  • Compilation and analysis of data from clinical trials involving 213Bi.

Main Results:

  • Established methods for producing 225Ac and 225Ac/213Bi generators are available.
  • Numerous preclinical studies demonstrate the therapeutic potential of 213Bi.
  • Clinical trials confirm the safety, feasibility, and efficacy of 213Bi targeted therapy.

Conclusions:

  • 213Bi is a viable radionuclide for targeted alpha therapy.
  • Advances in generator technology facilitate its clinical application.
  • Continued research and clinical trials are essential to further optimize 213Bi therapies.